Mesothelioma
📧 Sign up to get email alerts when something new happens for Mesothelioma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-19EMA Authorised: Opdivo (nivolumab) — Bristol-Myers Squibb Pharma EEIG
European Medicines Agency authorises Opdivo (nivolumab) for multiple cancer indications, including melanoma, non-small cell lung cancer, ren…
-
EMA approval · 2026-08-18EMA Authorised: Alimta (pemetrexed) — Eli Lilly Nederland B.V.
European Medicines Agency authorises Alimta (pemetrexed) for mesothelioma and non-small-cell lung carcinoma.
-
EMA approval · 2026-03-18EMA Authorised: Opdivo (nivolumab) — Bristol-Myers Squibb Pharma EEIG
EMA authorised Opdivo (nivolumab) for multiple cancer indications, including melanoma, Hodgkin lymphoma, renal cell carcinoma, non-small cel…
-
EMA approval · 2026-01-30EMA Authorised: Pemetrexed Accord (pemetrexed disodium hemipentahydrate) — Accord Healthcare S.L.U.
EMA authorised Pemetrexed Accord (pemetrexed disodium hemipentahydrate) for treatment of non-small cell lung cancer and mesothelioma; market…
-
EMA approval · 2025-07-25EMA Authorised: Armisarte (previously Pemetrexed Actavis) (pemetrexed diacid monohydrate) — Actavis Group PTC ehf
Armisarte (pemetrexed diacid monohydrate) has been authorised in the EU for non-small cell lung cancer and mesothelioma; Actavis Group PTC e…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2023-01-19EMA Authorised: Pemetrexed Baxter (pemetrexed disodium heptahydrate) — Baxter Holding B.V.
The EMA authorised Pemetrexed Baxter (pemetrexed disodium heptahydrate) for non-small cell lung carcinoma and mesothelioma.